Eltrombopag

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopaenic, Idiopathic

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Trial Timeline

Dec 21, 2010 โ†’ Oct 16, 2020

About Eltrombopag

Eltrombopag is a pre-clinical stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT01416311. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (11)

NCT IDPhaseStatus
NCT04837703Pre-clinicalActive
NCT05286164Phase 2UNKNOWN
NCT03988608Phase 2Completed
NCT03718533Phase 2Terminated
NCT03664518Phase 2Completed
NCT03524612Phase 2Completed
NCT02877212Phase 3UNKNOWN
NCT02323178Phase 1/2Completed
NCT01703169Phase 2Completed
NCT01715779Pre-clinicalCompleted
NCT01416311Pre-clinicalCompleted